NCT04581824 is a Phase 2 clinical trial of Dostarlimab in Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline.

Who is sponsoring NCT04581824?

NCT04581824 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT04581824?

Interventions in NCT04581824: Dostarlimab, Pembrolizumab, Chemotherapy.

What condition does NCT04581824 study?

NCT04581824 studies Lung Cancer, Non-Small Cell.

Is NCT04581824 still recruiting?

NCT04581824 is currently terminated. Last updated 8 August 2025.

Are results published for NCT04581824?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-08-08 · How we verify

NCT04581824

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Terminated Phase 2 Results posted Last updated 8 August 2025

What this trial tests

Phase 2 trial testing Dostarlimab in Lung Cancer, Non-Small Cell in 243 participants. Terminated before completion.

Timeline

19 November 2020

Primary endpoint
4 August 2022

10 September 2024

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	243
Start date	19 November 2020
Primary completion	4 August 2022
Estimated completion	10 September 2024
Sites	58 locations across France, Italy, Chile, Taiwan, Germany, Poland, South Korea, Argentina

Drugs / interventions tested

Dostarlimab (DOSTARLIMAB) — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →
Chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Lung Cancer, Non-Small Cell — all drugs for Lung Cancer, Non-Small Cell →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

18 and older, any sex, with Lung Cancer, Non-Small Cell. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Overall Survival (OS) Secondary · Up to approximately 46 months

OS was defined as the time from the date of randomization to the date of death by any cause.

Group	Value	95% CI
Dostarlimab + Chemotherapy	20.2	14.5 – 27.3
Pembrolizumab + Chemotherapy	15.9	11.6 – 19.3

Progression-free Survival (PFS) Secondary · Up to approximately 46 months

PFS was defined as the time from the date of randomization to the date of disease progression (PD) or death by any cause, whichever occurs first. PFS was evaluated using Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1 based on Investigator assessment. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).

Group	Value	95% CI
Dostarlimab + Chemotherapy	8.8	6.9 – 11.0
Pembrolizumab + Chemotherapy	6.8	4.9 – 7.1

Number of Participants With Treatment-emergent Adverse Event (TEAEs), TEAEs Leading to Death and TEAEs Leading to Treatment Discontinuation Secondary · Up to 46 months

AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. Number of participants with TEAEs, TEAEs leading to death, and TEAEs leading to treatment discontinuation are presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary).

TEAEs

Group	Value	95% CI
Dostarlimab + Chemotherapy	119
Pembrolizumab + Chemotherapy	119

TEAEs leading to death

Group	Value	95% CI
Dostarlimab + Chemotherapy	17
Pembrolizumab + Chemotherapy	12

TEAEs leading to treatment discontinuation

Group	Value	95% CI
Dostarlimab + Chemotherapy	35
Pembrolizumab + Chemotherapy	46

Number of Participants With Treatment Emergent Immune-related Adverse Event (irAE) Secondary · Up to 46 months

The irAEs are events which are severe or fatal and can occur in participants treated with monoclonal antibodies directed against immune checkpoints, including pembrolizumab and dostarlimab. While irAEs (eg, diarrhea/colitis, pneumonitis, nephritis, hypophysitis, adrenalitis, thyroiditis, severe skin reactions, uveitis, myocarditis, and hepatotoxicity) usually occur during treatment, symptoms can also manifest after discontinuation of treatment. AEs were coded using the MedDRA dictionary.

Group	Value	95% CI
Dostarlimab + Chemotherapy	38
Pembrolizumab + Chemotherapy	47

Number of Participants With Serious AEs Secondary · Up to approximately 46 months

An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is an important medical event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the above outcomes. SAEs are subset of AEs. AEs were coded using the MedDRA dictionary.

Group	Value	95% CI
Dostarlimab + Chemotherapy	51
Pembrolizumab + Chemotherapy	61

Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline Secondary · Up to approximately 46 months

Normal ranges were 30 to 110 units per liter (U/L) (Amylase); 4. 5 to 5. 6 milligram/deciliters (mg/dL) (Calcium); 96 to 100 milliequivalents (mEq)/ L (Chloride); 2. 5 to 4.5 mg/dL (Phosphate); 6 to 8.3 grams/L (protein); 6 to 24 millimoles/L (Urea) and 7 to 20 mg/dL (Urea nitrogen). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" categor

Amylase, To Low

Group	Value	95% CI
Dostarlimab + Chemotherapy	8
Pembrolizumab + Chemotherapy	11

Amylase, To Normal or No Change

Group	Value	95% CI
Dostarlimab + Chemotherapy	76
Pembrolizumab + Chemotherapy	76

Amylase, To High

Group	Value	95% CI
Dostarlimab + Chemotherapy	34
Pembrolizumab + Chemotherapy	30

Calcium, To Low

Group	Value	95% CI
Dostarlimab + Chemotherapy	42
Pembrolizumab + Chemotherapy	39

Calcium, To Normal or No Change

Group	Value	95% CI
Dostarlimab + Chemotherapy	60
Pembrolizumab + Chemotherapy	65

Calcium, To High

Group	Value	95% CI
Dostarlimab + Chemotherapy	25
Pembrolizumab + Chemotherapy	16

Chloride, To Low

Group	Value	95% CI
Dostarlimab + Chemotherapy	34
Pembrolizumab + Chemotherapy	26

Chloride, To Normal or No Change

Group	Value	95% CI
Dostarlimab + Chemotherapy	65
Pembrolizumab + Chemotherapy	69

Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline Secondary · Up to approximately 46 months

Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils); 41 to 50 percentage of red blood cells (RBC) in blood (hematocrit); 80-100 femtoliters (fl) (erythrocytes \[referred as Ery\] mean corpuscular volume (EMCV)); 2 to 8 percentage of WBC (monocytes); and Women: 4.2 to 5.4 million RBC/ microliter (mcL) of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to

Basophils, To Low

Group	Value	95% CI
Dostarlimab + Chemotherapy	12
Pembrolizumab + Chemotherapy	9

Basophils, To Normal or No Change

Group	Value	95% CI
Dostarlimab + Chemotherapy	72
Pembrolizumab + Chemotherapy	75

Basophils, To High

Group	Value	95% CI
Dostarlimab + Chemotherapy	19
Pembrolizumab + Chemotherapy	19

Hematocrit, To Low

Group	Value	95% CI
Dostarlimab + Chemotherapy	73
Pembrolizumab + Chemotherapy	64

Hematocrit, To Normal or No Change

Group	Value	95% CI
Dostarlimab + Chemotherapy	43
Pembrolizumab + Chemotherapy	50

Hematocrit, To High

Group	Value	95% CI
Dostarlimab + Chemotherapy	3
Pembrolizumab + Chemotherapy	1

EMCV, To Low

Group	Value	95% CI
Dostarlimab + Chemotherapy	6
Pembrolizumab + Chemotherapy	11

EMCV, To Normal or No Change

Group	Value	95% CI
Dostarlimab + Chemotherapy	59
Pembrolizumab + Chemotherapy	54

Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline Secondary · Up to approximately 46 months

Urine samples were collected to assess urine Bilirubin, glucose, ketones, Leukocyte Esterase, Nitrite, occult blood and Protein using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as No Change/Decreased, Increase to TRACE, Increase to +, Increase to ++, Increase to +++ and Increase to ++++. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Bilirubin, No Change/Decreased

Group	Value	95% CI
Dostarlimab + Chemotherapy	86
Pembrolizumab + Chemotherapy	66

Bilirubin, Increase to TRACE

Group	Value	95% CI
Dostarlimab + Chemotherapy	0
Pembrolizumab + Chemotherapy	0

Bilirubin, Increase to +

Group	Value	95% CI
Dostarlimab + Chemotherapy	4
Pembrolizumab + Chemotherapy	3

Bilirubin, Increase to ++

Group	Value	95% CI
Dostarlimab + Chemotherapy	0
Pembrolizumab + Chemotherapy	0

Bilirubin, Increase to +++

Group	Value	95% CI
Dostarlimab + Chemotherapy	0
Pembrolizumab + Chemotherapy	0

Bilirubin, Increase to ++++

Group	Value	95% CI
Dostarlimab + Chemotherapy	0
Pembrolizumab + Chemotherapy	0

Glucose, No Change/Decreased

Group	Value	95% CI
Dostarlimab + Chemotherapy	79
Pembrolizumab + Chemotherapy	57

Glucose, Increase to TRACE

Group	Value	95% CI
Dostarlimab + Chemotherapy	2
Pembrolizumab + Chemotherapy	1

Change From Baseline (CFB) in Thyroid Functions: Free Triiodothyronine (T3) and Free Thyroxine (T4) Secondary · Up to approximately 46 months

Blood samples were collected for the assessment Free Triiodothyronine (T3) and Free Thyroxine (T4).

Triiodothyronine, Free, Baseline

Group	Value	95% CI
Dostarlimab + Chemotherapy	4.48026	± 1.638746
Pembrolizumab + Chemotherapy	4.48540	± 1.066597

Triiodothyronine, Free, CFB to Cycle 2 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	-0.12423	± 2.071042
Pembrolizumab + Chemotherapy	-0.24330	± 1.026993

Triiodothyronine, Free, CFB to Cycle 4 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	-0.00187	± 2.206972
Pembrolizumab + Chemotherapy	-0.11796	± 1.413190

Triiodothyronine, Free, CFB to Cycle 6 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	-0.15030	± 2.128584
Pembrolizumab + Chemotherapy	-0.37705	± 1.117516

Triiodothyronine, Free, CFB to Cycle 8 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	0.11483	± 2.738875
Pembrolizumab + Chemotherapy	-0.43073	± 1.123017

Triiodothyronine, Free, CFB to Cycle 10 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	-0.25993	± 2.187046
Pembrolizumab + Chemotherapy	-0.23819	± 1.273369

Triiodothyronine, Free, CFB to Cycle 12 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	-0.04347	± 2.817465
Pembrolizumab + Chemotherapy	5.82171	± 34.328615

Triiodothyronine, Free, CFB to Cycle 14 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	-0.61895	± 2.558169
Pembrolizumab + Chemotherapy	-0.33501	± 1.597219

Change From Baseline in Thyroid Function: Thyrotropin (TSH) Secondary · Up to approximately 46 months

Blood samples were collected for the assessment of Thyroid Function Thyrotropin (TSH).

Baseline

Group	Value	95% CI
Dostarlimab + Chemotherapy	1.853	± 1.8354
Pembrolizumab + Chemotherapy	1.904	± 1.7421

CFB to Cycle 2 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	0.225	± 3.7642
Pembrolizumab + Chemotherapy	-0.497	± 1.7405

CFB to Cycle 4 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	1.285	± 9.4283
Pembrolizumab + Chemotherapy	-0.622	± 1.7892

CFB to Cycle 6 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	1.123	± 8.4596
Pembrolizumab + Chemotherapy	2.006	± 21.0213

CFB to Cycle 8 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	2.454	± 9.7235
Pembrolizumab + Chemotherapy	2.648	± 22.9952

CFB to Cycle 10 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	3.233	± 12.1571
Pembrolizumab + Chemotherapy	1.986	± 12.8377

CFB to Cycle 12 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	2.448	± 9.8590
Pembrolizumab + Chemotherapy	1.138	± 10.9780

CFB to Cycle 14 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	1.282	± 4.2566
Pembrolizumab + Chemotherapy	1.734	± 9.0539

Change From Baseline in Thyroid Functions: Triiodothyronine (T3) and Thyroxine (T4) Secondary · Up to approximately 46 months

Blood samples were collected for the assessment of Triiodothyronine (T3) and Thyroxine (T4).

Triiodothyronine, Baseline

Group	Value	95% CI
Dostarlimab + Chemotherapy	1.68399	± 0.308404
Pembrolizumab + Chemotherapy	1.48287	± 0.526037

Triiodothyronine, CFB to Cycle 2 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	0.06903	± 0.172873
Pembrolizumab + Chemotherapy	-0.58292

Triiodothyronine, CFB to Cycle 4 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	-0.41878	± 0.353613

Triiodothyronine, CFB to Cycle 6 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	-0.21476

Thyroxine, Baseline

Group	Value	95% CI
Dostarlimab + Chemotherapy	72.72912	± 46.845564
Pembrolizumab + Chemotherapy	85.29069	± 38.027652

Thyroxine, CFB to Cycle 2 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	16.06393	± 38.489073
Pembrolizumab + Chemotherapy	-3.12689	± 11.544100

Thyroxine, CFB to Cycle 4 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	10.16002	± 47.746764
Pembrolizumab + Chemotherapy	12.22592	± 30.578995

Thyroxine, CFB to Cycle 6 Day 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	9.83083	± 30.658114
Pembrolizumab + Chemotherapy	-2.45916	± 27.497527

Number of Participants With Worst-case Grade Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Secondary · Up to approximately 46 months

DBP and SBP were measured in a semi-supine position after 5 minutes rest. Grades were derived based on numeric criteria as defined in Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Systolic Blood Pressure (SBP): Grade 0 (\<120 Millimetre of mercury (mmHg)), Grade 1 (120-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg). Diastolic Blood Pressure (DBP): Grade 0 (\<80 mmHg), Grade 1 (80-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg). An increase is defined as an increase in the CTCAE grade relative to the Baseline grade. Only those participants with grade increa

DBP, Increase to Grade 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	36
Pembrolizumab + Chemotherapy	27

DBP, Increase to Grade 2

Group	Value	95% CI
Dostarlimab + Chemotherapy	35
Pembrolizumab + Chemotherapy	25

DBP, Increase to Grade 3

Group	Value	95% CI
Dostarlimab + Chemotherapy	6
Pembrolizumab + Chemotherapy	7

SBP, Increase to Grade 1

Group	Value	95% CI
Dostarlimab + Chemotherapy	24
Pembrolizumab + Chemotherapy	18

SBP, Increase to Grade 2

Group	Value	95% CI
Dostarlimab + Chemotherapy	34
Pembrolizumab + Chemotherapy	24

SBP, Increase to Grade 3

Group	Value	95% CI
Dostarlimab + Chemotherapy	8
Pembrolizumab + Chemotherapy	11

Adverse events — posted to ClinicalTrials.gov

Time frame: All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected from Day 1 and up to approximately 46 months.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Dostarlimab + Chemotherapy

Serious: 51/121 (42%)

Deaths: 80/121

Pembrolizumab + Chemotherapy

Serious: 61/122 (50%)

Deaths: 91/122

Serious adverse events (102 terms)

Reaction	System	Dostarlimab + Chemotherapy	Pembrolizumab + Chemotherapy
Pneumonia	Infections and infestations	—	—
Anaemia	Blood and lymphatic system disorders	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—
Pneumonitis	Respiratory, thoracic and mediastinal disorders	—	—
Febrile neutropenia	Blood and lymphatic system disorders	—	—
Pyrexia	General disorders	—	—
COVID-19	Infections and infestations	—	—
Pleural effusion	Respiratory, thoracic and mediastinal disorders	—	—
Neutropenia	Blood and lymphatic system disorders	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—
Asthenia	General disorders	—	—
Sudden death	General disorders	—	—
Respiratory tract infection	Infections and infestations	—	—
Chronic obstructive pulmonary disease	Respiratory, thoracic and mediastinal disorders	—	—
Haemoptysis	Respiratory, thoracic and mediastinal disorders	—	—
Respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—
Pancytopenia	Blood and lymphatic system disorders	—	—
Cardiac arrest	Cardiac disorders	—	—
Pericardial effusion	Cardiac disorders	—	—
Colitis	Gastrointestinal disorders	—	—
Constipation	Gastrointestinal disorders	—	—
Diarrhoea	Gastrointestinal disorders	—	—
Pain	General disorders	—	—
Sepsis	Infections and infestations	—	—
Septic shock	Infections and infestations	—	—

Other adverse events (44 terms — click to expand)

Reaction	System	Dostarlimab + Chemotherapy	Pembrolizumab + Chemotherapy
Anaemia	Blood and lymphatic system disorders	—	—
Asthenia	General disorders	—	—
Nausea	Gastrointestinal disorders	—	—
Constipation	Gastrointestinal disorders	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—
Neutropenia	Blood and lymphatic system disorders	—	—
Vomiting	Gastrointestinal disorders	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—
Diarrhoea	Gastrointestinal disorders	—	—
Blood creatinine increased	Investigations	—	—
Fatigue	General disorders	—	—
Rash	Skin and subcutaneous tissue disorders	—	—
Pyrexia	General disorders	—	—
Alanine aminotransferase increased	Investigations	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—
Oedema peripheral	General disorders	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—
Respiratory tract infection	Infections and infestations	—	—
Aspartate aminotransferase increased	Investigations	—	—
Hypothyroidism	Endocrine disorders	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—
COVID-19	Infections and infestations	—	—
Platelet count decreased	Investigations	—	—
Weight decreased	Investigations	—	—
Hypomagnesaemia	Metabolism and nutrition disorders	—	—
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	—	—
Dizziness	Nervous system disorders	—	—
Headache	Nervous system disorders	—	—
Hypertension	Vascular disorders	—	—
Hyperthyroidism	Endocrine disorders	—	—
Stomatitis	Gastrointestinal disorders	—	—
Chest pain	General disorders	—	—
Conjunctivitis	Infections and infestations	—	—
Pneumonia	Infections and infestations	—	—
Blood alkaline phosphatase increased	Investigations	—	—
Gamma-glutamyltransferase increased	Investigations	—	—
Hyperglycaemia	Metabolism and nutrition disorders	—	—
Mucosal inflammation	General disorders	—	—

Most-reported serious reactions: Pneumonia, Anaemia, Dyspnoea, Pneumonitis, Febrile neutropenia, Pyrexia, COVID-19, Pleural effusion.

Data from ClinicalTrials.gov NCT04581824 adverse events section.

Sponsor's own description

NSCLC comprises of approximately 84 percent (%) of all lung cancers and is often diagnosed at advanced stage due to poor prognosis. Dostarlimab is an immunoglobulin G (IgG)4 kappa humanized monoclonal antibody (mAb) that binds with high affinity to programmed cell death protein 1 (PD 1), resulting in inhibition of binding to programmed death ligand 1 (PD L1) and programmed death ligand 2 (PD L2). This study aims to compare the efficacy and safety PD-1 inhibitors dostarlimab and pembrolizumab, when administered in combination with chemotherapy (pemetrexed, cisplatin and carboplatin), in participants with non-squamous NSCLC without a known sensitizing epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or receptor tyrosine kinase-1 (ROS-1) mutation, BRAF V600E mutation, or other genomic aberration for which an approved targeted therapy is available. A total of approximately 240 participants will be enrolled in the study for a period of 5 years.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Dostarlimab: A Review.
Costa B, Vale N. · · 2022 · cited 39× · PMID 35892341 · DOI 10.3390/biom12081031
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.
Lim SM, Peters S, Ortega Granados AL, Pinto GDJ, et al · · 2023 · cited 22× · PMID 37951954 · DOI 10.1038/s41467-023-42900-4
Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review).
Lu J, Ding J, Liu Z, Chen T. · · 2022 · cited 14× · PMID 34981814 · DOI 10.3892/ijo.2022.5302
Immunotherapy in lung cancer brain metastases.
Paisana E, Cascão R, Alvoeiro M, Félix F, et al · · 2025 · cited 8× · PMID 40328894 · DOI 10.1038/s41698-025-00901-0
Drug resistance mechanism and reversal strategy in lung cancer immunotherapy.
Xu Y, Liu Y, Ge Y, Li H, et al · · 2023 · cited 8× · PMID 37795038 · DOI 10.3389/fphar.2023.1230824
Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors.
Kareff SA, Samtani S, Burotto M, Prasad V, et al · · 2021 · cited 3× · PMID 34590006 · DOI 10.1016/j.jtocrr.2021.100149
Development of a Joint Tumor Size-Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-Making.
Struemper H, Rathi C, Muliaditan M, Goulooze SC, et al · · 2025 · cited 2× · PMID 39985158 · DOI 10.1002/psp4.70002
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
Reck M, Granados ALO, de Marinis F, Meyers O, et al · · 2024 · cited 1× · PMID 39378565 · DOI 10.1016/j.ejca.2024.115050

Verify or expand the search:

Other trials of Dostarlimab

Trials testing the same drug.

NCT07408063 — A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Res · Phase 2 · not yet recruiting
NCT07381777 — XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Lo · Phase 2 · not yet recruiting
NCT06405230 — Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Or · Phase 1, PHASE2 · recruiting
NCT07336147 — Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine · Phase 2 · recruiting
NCT07108270 — A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recur · Phase 2 · recruiting

Other recruiting trials for Lung Cancer, Non-Small Cell

Currently open trials in the same condition.

NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
NCT06405230 — Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Or · Phase 1, PHASE2 · recruiting
NCT07166003 — Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer · recruiting
NCT06942845 — Exploration of Risk Factors for Postoperative Cerebral Infarction in Lung Cancer Patients: a Retrospective Single-centre · active not recruiting
NCT06687408 — Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04581824 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 8 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04581824.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing